β-actin Recombinant Mouse Monoclonal Antibody [45C07]
β-actin Recombinant Mouse Monoclonal Antibody [45C07](AWA80001):Dilution 1 10000,应用 WB,IHC-P,IF-C,IF-P,IP,FCM,来源 Mouse。
01产品图片
![点击查看大图 β-actin Recombinant Mouse Monoclonal Antibody [45C07]](../../assets/uploads/f015d2be9804-mvvpmr4y.webp)
02产品简介
β-actin Recombinant Mouse Monoclonal Antibody [45C07](AWA80001):Dilution 1 10000,应用 WB,IHC-P,IF-C,IF-P,IP,FCM,来源 Mouse。
03产品介绍
Human,Mouse,Rat,Pig,Monkey,Rabbit,Goat,Zebrafish,Dog,Chicken,Cow,Hamster
ACTB; Actin; cytoplasmic 1; Beta-actin; Actin β; Actin Beta; Beta-Actin; Beta actin; PS1TP5BP1; β-Actin; β-actin
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Affinity-chromatography
Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20°C storage.
认真做好每一个抗体, 每一个抗体都经过反复验证!
IP 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate.
Glaucoma is a leading cause of irreversible blindness, characterized by the progressive degeneration of retinal ganglion cells (RGCs) and optic nerve damage. Although current intraocular pressure (IOP)-lowering therapies exhibit varying degrees of efficacy in preventing RGC loss, neurodegeneration can persist even in cases where IOP remains within the normal range, underscoring the need for direct neuroprotective strategies. Emerging evidence suggests that neuroinflammation mediated by retinal microglia plays a pivotal role in the pathogenesis of glaucoma. Here, a nucleic acid-based nanotherapeutic platform is proposed that employs tetrahedral framework nucleic acids (tFNAs) conjugated with microRNA-124 (miR-124), referred to as Tmi, to achieve targeted immunomodulation. Compared with conventional delivery systems, this self-assembled nanostructure exhibits superior cellular penetration and nucleic acid protection capabilities. Mechanistic studies demonstrate that Tmi-mediated inhibition of the STAT3 pathway attenuates excessive microglial activation, reduces migration-associated inflammation, and suppresses pathological cell migration in an acute ocular hypertension model. This is an alternative treatment strategy beyond intraocular pressure control, offering greater possibilities for exploring therapies for acute high intraocular pressure glaucoma.
Authors:Zhouyu Yang, Ke Li, Xinru Li, Pei Zhong, Yuqian Hu, Xin Yao Authors:Xiqi Hu, Ya-nan Ma, Jun Peng, Zijie Wang, Yuchang Liang, Ying Xia Authors:Aijun Jia, Yueling Wang, Rimei Zhou, Likun Han
Despite the documented involvement of neutrophil extracellular traps (NETs) in various cancer types, their specific role in meningioma development remains understudied. Here, we report a mechanism by which the JAM3/Mac-1 interaction promotes meningioma development via NETs. We found that JAM3 knockdown in meningioma cells suppressed AKT phosphorylation, thereby reducing neutrophil migration and NET formation in co-culture; these effects were rescued by the AKT activator SC79. Co-IP confirmed the JAM3/Mac-1 interaction. In a xenograft model, JAM3 knockdown inhibited tumor growth and intratumoral NETs. Furthermore, NETs enhanced meningioma cell growth in vitro and in vivo , an effect abolished by DNase I. Conversely, Mac-1 knockdown in neutrophils impaired their function, which was also restored by SC79. Clinically, JAM3 expression correlated with Mac-1 and NET markers in meningioma samples. In conclusion, JAM3 promotes meningioma development by regulating the formation of NET through the Mac-1/AKT axis. These findings offer novel insights for treating these common primary tumors of the central nervous system.
Authors:Jing Zhang, Yipeng Dong, Xianghua Zhang, Tao Wu
Patients suffering from sepsis-induced acute lung injury (ALI) exhibit a high mortality rate, and their prognosis is closely associated with infiltration of neutrophils into the lungs. In this study, we found a significant elevation of CD64 + neutrophils, which highly expressed p75 neurotrophin receptor (p75 NTR ) in peripheral blood of mice and patients with sepsis-induced ALI. p75 NTR+ CD64 + neutrophils were also abundantly expressed in the lung of ALI mice induced by lipopolysaccharide. Conditional knock-out of the myeloid lineage's p75 NTR gene improved the survival rates, attenuated lung tissue inflammation, reduced neutrophil infiltration and enhanced the phagocytic functions of CD64 + neutrophils. In vitro, p75 NTR+ CD64 + neutrophils exhibited an upregulation and compromised phagocytic activity in blood samples of ALI patients. Blocking p75 NTR activity by soluble p75 NTR extracellular domain peptide (p75 ECD -Fc) boosted CD64 + neutrophil phagocytic activity and reduced inflammatory cytokine production via activation of the NF-κB pathway. The findings strongly indicate that p75 NTR+ CD64 + neutrophils are a novel pathogenic neutrophil subpopulation promoting sepsis-induced ALI.
Authors:Di Fu, Shan Gao, Jia-Nan Li, Yan-Hui Cui, Yan-Wei Luo, Yan-Jun Zhong, Qiao Li, Cong Luo, Ru-Ping Dai, Ru-Yi Luo, Zhao-Lan Hu Authors:Chen Zhen, Su Yongpeng, Liu Genglong, Yin Huimei, Zuo Yu, He Gege, Feng Ruijin, Zuo Liuer Authors:Hongyu Liu, Yali Deng, Mei Peng, Yanting Nie, Jingfei Chen
Danggui Buxue Decoction (DBD) has shown potential antitumor effects in a variety of cancers. This study aims to delve into the effects and mechanisms of DBD on the metastasis of triple-negative breast cancer (TNBC). The mouse model of TNBC was constructed, and the function of DBD was investigated. The active components and core targets of DBD on TNBC were identified through liquid chromatography-mass spectrometry, network pharmacology, and molecular docking techniques. A set of in vitro experiments was conducted to examine the key components and core targets of DBD that affect the metastasis of TNBC. DBD inhibited the growth and metastasis of TNBC tumors. Formononetin is one of the key active ingredients of DBD, exerts antitumor effects by targeting Snail family transcriptional repressor 2 (SNAI2). The addition of DBD or Formononetin inhibited the malignant activity and reduced the expression of SNAI2. However, this ability of Formononetin was reversed due to the overexpression of the SNAI2 gene. Formononetin inhibits the metastasis of TNBC by downregulating SNAI2. The outcomes offer a basis for the future clinical utilization of DBD and Formononetin in TNBC therapy.
Authors:Kui Li, Ting Zhou, Ruoxia Wu, Jiaqing Xiong
相关资料下载:说明书(点击从官网下载)
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2016 年
- 所在地
- 湖南
- 收录条目
- 498 个
- 平台核验
- 平台代管
06品牌与供应商
公司产品涵盖抗体、细胞、培养基、质粒载体等多个领域,致力于为生命科学研究提供可靠的工具与解决方案。自创立以来,艾碧维始终秉持“求实、诚挚、勤勉、克己”的发展理念,坚持以自主研发与持续创新为核心动力。公司拥有百余人的团队,其中硕士及以上学历生物医学专业人才占比超过30%,包括博士4人,构建起一支结构合理、专业扎实的研发与服务队伍。通过设立研发部、生产部、市场与营销部、财务部等多功能部门,公司实现了从产品开发到市场推广的全流程管控。艾碧维不仅敢于质疑现状,积极为生命科学家突破技术壁垒提供支撑,更注重与客户的深度互动与合作,通过持续收集反馈、开展研发协作,提前预见并解决潜在问题。未来,公司将继续秉持“助力科研创新,让实验更简单”的使命,一步一个脚印地打造具有国际领先水平的技术研发与产业化平台,为全球生命科学领域的进步持续赋能。注意: 1.本公司产品仅供科研使用。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
艾碧维 在本目录共 498 个条目,除本条外还有:
科研在线(TeleVM). β-actin Recombinant Mouse Monoclonal Antibody [45C07](AWA80001)[EB/OL]. 产品目录, 2026-10-31. https://www.suprotek.cn/products/item/actin-recombinant-mouse-monoclonal-antibody-45c07.html.
TeleVM. (2026, October 31). β-actin Recombinant Mouse Monoclonal Antibody [45C07](AWA80001). 产品目录. https://www.suprotek.cn/products/item/actin-recombinant-mouse-monoclonal-antibody-45c07.html
@misc{biocsp_item_actin_recombinant_mouse_monoclonal_antibody_45c07,
title = {β-actin Recombinant Mouse Monoclonal Antibody [45C07](AWA80001)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-10-31,产品目录},
url = {https://www.suprotek.cn/products/item/actin-recombinant-mouse-monoclonal-antibody-45c07.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源